Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | FGF23 | Q9GZV9 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 7/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5241647 | 1.00 | ALDH1A1 (0.47) | ALDH1A1FGF23HPGDALOX5HTT | |
| SCHEMBL23229108 | 0.81 | ALOX5 (0.40) | ALDH1A1HPGDALOX5HTTLMNA | |
| SCHEMBL7756750 | 0.79 | ALOX12 (0.46) | ALDH1A1FGF23HPGDHTTLMNA | |
| SCHEMBL7756773 | 0.79 | HPGD (0.41) | ALDH1A1FGF23HPGDHTTLMNA | |
| SCHEMBL7756754 | 0.79 | ALOX12 (0.46) | ALDH1A1FGF23HPGDHTTLMNA | |
| SCHEMBL7756778 | 0.79 | HPGD (0.41) | ALDH1A1FGF23HPGDHTTLMNA | |
| SCHEMBL10075899 | 0.78 | CA12 (0.52) | ALDH1A1ALOX5BACE1KDM4E | |
| SCHEMBL9959739 | 0.78 | CA12 (0.52) | ALDH1A1ALOX5BACE1KDM4E | |
| SCHEMBL6779682 | 0.77 | FGF23 (0.57) | ALDH1A1FGF23HPGDHTTLMNA | |
| SCHEMBL14572070 | 0.76 | ABCB1 (0.38) | ALDH1A1ALOX5HTTLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0702008-B1 | Method for producing 1,2-benzisothiazol-3-ones | SUMITOMO SEIKA CHEMICALS (JP) | 2001-08-29 | — | — | EP | claimed |
| US-5856504-A | TREATING A 2-(ALKYLTHIO)BENZALDEHYDE OXIME WITH A HALOGEN COMPOUND | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1999-01-05 | — | — | US | claimed |
| US-5773626-A | HALOGENATION OF A 2-(ALKYLTHIO)BENZALDEHYDE OXIME | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1998-06-30 | — | — | US | claimed |
| EP-0805151-A1 | PROCESSES FOR PRODUCING ISOTHIAZOLE DERIVATIVES | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1997-11-05 | — | — | EP | claimed |
| EP-0702008-A2 | Method for producing 1,2-benzisothiazol-3-ones | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1996-03-20 | — | — | EP | claimed |
| US-7776847-B2 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1853573-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | Rigel Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | disclosed |
| WO-2006091858-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-0702008-B1 | Method for producing 1,2-benzisothiazol-3-ones | SUMITOMO SEIKA CHEMICALS (JP) | 2001-08-29 | — | — | EP | disclosed |
| EP-1081141-A1 | Method for producing 1,2-benzisothiazol-3-ones | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2001-03-07 | — | — | EP | disclosed |
| US-5856504-A | TREATING A 2-(ALKYLTHIO)BENZALDEHYDE OXIME WITH A HALOGEN COMPOUND | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1999-01-05 | — | — | US | disclosed |
| US-5773626-A | HALOGENATION OF A 2-(ALKYLTHIO)BENZALDEHYDE OXIME | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1998-06-30 | — | — | US | disclosed |
| EP-0805151-A1 | PROCESSES FOR PRODUCING ISOTHIAZOLE DERIVATIVES | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1997-11-05 | — | — | EP | disclosed |
| US-5633384-A | FROM O-ALKYLTHIOBENZONITRILES | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1997-05-27 | — | — | US | disclosed |
| EP-0702008-A2 | Method for producing 1,2-benzisothiazol-3-ones | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1996-03-20 | — | — | EP | disclosed |
| EP-0174046-A2 | Ether herbicides | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1986-03-12 | — | — | EP | disclosed |
| US-4104379-A | DOPAMINERGIC ACTIVITY | SMITHKLINE CORPORATION (US) | 1978-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | HAVCR2, ZC3HAV1, MAVS | ALDH1A1 227/4885FGF23 3798/4885HPGD 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.